The Men’s Health Foundation is one of nine Centers of Excellence for Biomedical Prevention Services (PEP/PrEP) in Los Angeles County. With a robust research division, its comprehensive care clinic, the Southern California Men’s Medical Group, and outreach, prevention and education programs, the Men’s Health Foundation is at the forefront of HIV prevention and care in Los Angeles. Men’s Health Foundation has four PrEP Navigators who can provide full PEP/PrEP services, including clinical visits and prescription, to anyone, regardless of their ability to pay. We can provide PEP/PrEP access to anyone who lives in Los Angeles County if uninsured, underinsured or insured, as we have a menu of PrEP options. We can also help with benefits to access Medi-Cal or Covered California’s exchange of insurance options.
To access PEP/PrEP services, please call (310) 550-1010 and request PEP or PrEP and get connected to one of our skilled PrEP Navigators, Efren, William, Robert or Jake. If after hours, press the PrEP number on recording and a Navigator will get back to you within 24 hours.
Men’s Health Foundation will be offering FREE Meningitis vaccines regardless of whether you have health insurance. Stop by our booth at:
8578 Santa Monica Blvd (near 24 Hour Fitness)
West Hollywood, CA 90069
Did you know there is currently a Meningitis outbreak in Southern California? The LA County Department of Public Health is hosting a FREE Meningitis vaccine clinic in our office on Friday, July 29 from 9am to 3pm. Vaccinations should take less than 5 minutes, and no insurance is required! Less than 5% of gay men are currently vaccinated… let’s change that!
After tens of thousands of PrEP successes, the first documented case of someone becoming poz includes rare multiclass drug resistance.
It’s been nearly two years since the Centers for Disease Control and Prevention issued historic guidelines recommending that thousands of Americans—particularly gay and bi men, transgender women, injection drug users, and partners of HIV-positive individuals—start taking Truvada as pre-exposure prophylaxis (or PrEP) to prevent HIV infection.
The prevention method has shown to be 99 percent effective at preventing HIV transmission among those who take it daily as prescribed and, as was reported at the Conference on Retroviruses and Opportunistic Infections this week, it’s even 86 percent effective among those using it “on demand” (essentially one dose two to 24 hours before sex, and then twice more the two days following sex).
Truvada as PrEP has had its critics from the get-go, notably Michael Weinstein, the head of AIDS Healthcare Foundation, who has led what some activists called a moral crusade against the drug. But many scientists, doctors, public health experts, and activists have heralded the prevention method as part of the necessary one-two punch needed to get HIV and AIDS numbers lowered in the U.S. (the other part being treatment as
This week, Dr. Mills spoke to a group of over 40 local HIV social workers and health care providers at the second Treatment Update Luncheon. Topics included results from the START study, latest advances in HIV treatment research, and current clinical research opportunities available through Mills Clinical Research. Stay tuned for information about future events!
AIDS United, in partnership with the Centers of Disease Control and Prevention (CDC) and Gay Men’s Health Crisis (GMHC), has recently released their PrEP ToolKit.
This toolkit was created as a resource for staff in community-based organizations (CBOs) to support their efforts at educating communities about and increasing access to PrEP. It is divided into the following seven sections:
- What is PrEP?
- Who Is PrEP for?
- PrEP Research: How we know it works
- Kinds of PrEP
- Preparing your clients for PrEP
- PrEP cost and payment resources
- General PrEP resources
Various downloadable resources are linked throughout the document, including: “Questions about PrEP and the Doctor,” the “PrEP Index,” and a one-page reference of PrEP studies.
You can access the toolkit here.
Last week, the CDC’s Morbidity and Mortality Weekly Report (MMWR) released estimated percentages and numbers of adults with indications for PrEP. Among adult MSM aged 18-59 years in the United States who report sexual activity in the past year, approximately 25% have indications for PrEP to prevent HIV acquisition, compared with approximately 18% of persons who inject drugs and 0.4% of heterosexually active adults.
The high percentage of MSM with PrEP indications is consistent with the high number of new HIV infections among MSM. The high percentage of persons who inject drugs with PrEP indications reflects the relatively high percentage who report using a needle after it was used by another injector. The low percentage and high absolute number of heterosexually active adults is a reflection of the large heterosexually active U.S. population and the low rate of new HIV diagnoses in these adults. The actual risk for acquiring HIV infection for each of these transmission risk groups differs based on efficiency of transmission routes and likelihood of exposure to HIV.
See more about the research here.
This Tuesday, the Men’s Health Foundation attended the “EMPOWE[RED]: Getting to zero, a generation free of HIV” event at Mark Taper Auditorium, December 1, 2015. Health organizations and community members from around LA County got together to remember the history of AIDS, speak candidly about its current place in society, and look forward toward an AIDS-free generation.
The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.
The CDC estimates that 1.2 million persons ages 13 years and older are living with HIV infection, and that more than another 150,000 persons in this age range have HIV but are unaware of their infection. Over the past decade, the number of people living with HIV has increased, while the annual number of new HIV infections has remained relatively stable.
“Today’s approval of a fixed dose combination containing a new form of tenofovir provides another effective, once daily complete regimen for patients with HIV-1 infection,” said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research.
Today’s approval of a fixed dose combination containing a new form of tenofovir provides another effective, once daily complete regimen for patients with HIV-1 infection.
Genvoya is approved for use in HIV-infected adults and children ages 12 years and older weighing at least 35 kilograms (77 pounds) who have never taken HIV therapy (treatment-naïve) and HIV-infected adults